|
|
Other links at Articles > Nephrology |
| 5. |
Open Letter to the FDA: New Drug Trials Must Be Relevant
|
|
|
The insistence of the FDA that only narrowly defined regimens are allowed in the control group in prospective randomized trials for drug registration has led to many undesirable consequences.
American Journal of Transplantation
|
|
|